Antibodies harvested from the blood of paediatricians are up to 25 times better at protecting against the common respiratory ...
Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for ...
Health officials say RSV activity can still fluctuate through March.
GlobalData on MSN
MSD reports Phase III SMART trial outcomes for infants’ RSV risk
The results indicate that safety in children under two years was consistent across both RSV seasons receiving Enflonsia.
RSV cases are high in New York State.The New York State Department of Health says there were 5,785 RSV cases and 819 ...
Flu claims 5 more US children’s lives as virus continues circulating at moderate to very high levels
Nine states are seeing moderate flu activity, while 26 report high or very high case rates. Flu test positivity continues to ...
Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local ...
New FDA-approved immunizations are crucial for protecting infants from RSV, a leading cause of hospitalization for babies ...
Clinicians underutilize RSV testing in adults with respiratory or cardiac exacerbations, potentially obscuring the true burden of disease.
Data shows that ER visits and hospital admissions for RSV have been climbing in New Jersey since early October. Currently, ER visits for RSV are “high” or “very high” in more than half of New Jersey ...
There's been an uptick in flu cases in the past week, which health officials are monitoring, local officials told Patch.
Merck (MRK) reports positive Phase 3 SMART trial results for ENFLONSIA in high-risk infants/children vs RSV, with consistent safety and dosing—read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results